Ching-Liang Ho

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su et al. · The Lancet Oncology · 2012 · 405 citations

Medicine, Oncology, Pharmacotherapy +13

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

Animesh Pardanani, Stephanie R. Brockman, Sarah F. Paternoster et al. · Blood · 2004 · 314 citations · Full text

Medicine, Immunology, Pathology +10

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Chao‐Hua Chiu, Cheng‐Ta Yang, Jin‐Yuan Shih et al. · Journal of Thoracic Oncology · 2015 · 245 citations

Medicine, Oncology, Pharmacology +14

The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan

Wei‐Liang Chen, Wen‐Chiuan Tsai, Tsu-Yi Chao et al. · Annals of Hematology · 2009 · 48 citations

Veterinary Medicine, Oncology, Pathology +16

Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection—A Double Blind, Multi-Center, Randomized Phase IV Study

Cheng‐Hsu Wang, Cheng-Yao Lin, Jen‐Shi Chen et al. · Cancers · 2019 · 43 citations · Full text

Medicine, Oncology, Pharmacology +14